Page 2 - Thomas Baumert News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Three months after Alentis Therapeutics’ lead program posted positive Phase 1 data, the biotech has raised cash to advance that program to mid-stage testing in fibrosis. The Series C financing will also support a cancer drug candidate ready to start human testing.

An onslaught of common childhood viruses may have been behind the mysterious outbreak of cases of severe liver damage in children that began popping up in late 2021, as lockdowns were relaxed and schools reopened.

Last year, the World Health Organisation (WHO) reported 1,010 probable cases of liver disease worldwide - now researchers are trying to find the potential link between hepatitis and other common viruses.

Strong evidence that AAV2 and underlying genetic predisposition played a key role in child hepatitis cases There is now strong evidence that the…

THERE is "convincing evidence" to indicate that a mysterious outbreak of severe hepatitis which sickened hundreds of young children…

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1) ALE.F02 found to be well tolerated at all doses with a good safety profile and

Brings over thirty years of world-class R&D leadership with particular focus on kidney, liver and oncology and success across the entire spectrum of drug development Alentis Therapeutics ("Alentis"

FDA greenlights Alentis Phase 1 protocol study design Alentis to begin transition from pre-clinical to clinical Alentis Therapeutics, AG today announc

Press release content from Business Wire. The AP news staff was not involved in its creation.